Research ArticleArticle
Including Health Equity Considerations in Development of Instruments for Rheumatology Research: An Introduction to a Novel OMERACT Paradigm
Jennifer O'Neill, Tamara Rader, Francis Guillemin, Annelies Boonen, Robin Christensen, Anne Lyddiatt, Jordi Pardo Pardo, Vivian Welch, Jasvinder A. Singh and Peter Tugwell
The Journal of Rheumatology October 2013, jrheum.130812; DOI: https://doi.org/10.3899/jrheum.130812
Jennifer O'Neill
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Tamara Rader
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Francis Guillemin
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Annelies Boonen
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Robin Christensen
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Anne Lyddiatt
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Jordi Pardo Pardo
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Vivian Welch
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Jasvinder A. Singh
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Peter Tugwell
From the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Université de Lorraine, Nancy, France; Maastricht University Medical Centre, Maastricht, Netherlands; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark; Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; University of Ottawa, Department of Medicine, Department of Epidemiology and Community Medicine Faculty of Medicine, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada. P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. J. O’Neill, MSc, Coordinator, Campbell and Cochrane Equity Methods Group; T. Rader, MLIS, Knowledge Translation Specialist and Trials Search Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; F. Guillemin, MD, PhD, Ecole de santé publique, Faculté de Médecine, Université de Lorraine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; R. Christensen, MSc, PhD, Head of Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg; A. Lyddiatt, BA, Consumer Coordinator, Cochrane Musculoskeletal Group, University of Ottawa; J. Pardo Pardo, LDO, Cochrane Musculoskeletal Group, University of Ottawa; V. Welch, PhD, Deputy Director, Centre for Global Health, University of Ottawa; J. Singh, MBBS, MPH, University of Alabama at Birmingham; P. Tugwell, MD, MSc, Canada Research Chair in Health Equity, Professor of Medicine and Epidemiology, Department of Medicine, University of Ottawa. Address correspondence to J. O’Neill, University of Ottawa, Institute of Population Health, 1 Stewart St., Ottawa, Ontario K1N6N5, Canada. E-mail: Jennifer.ONeill@uottawa.ca.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Including Health Equity Considerations in Development of Instruments for Rheumatology Research: An Introduction to a Novel OMERACT Paradigm
Jennifer O'Neill, Tamara Rader, Francis Guillemin, Annelies Boonen, Robin Christensen, Anne Lyddiatt, Jordi Pardo Pardo, Vivian Welch, Jasvinder A. Singh, Peter Tugwell
The Journal of Rheumatology Oct 2013, jrheum.130812; DOI: 10.3899/jrheum.130812
Including Health Equity Considerations in Development of Instruments for Rheumatology Research: An Introduction to a Novel OMERACT Paradigm
Jennifer O'Neill, Tamara Rader, Francis Guillemin, Annelies Boonen, Robin Christensen, Anne Lyddiatt, Jordi Pardo Pardo, Vivian Welch, Jasvinder A. Singh, Peter Tugwell
The Journal of Rheumatology Oct 2013, jrheum.130812; DOI: 10.3899/jrheum.130812